HC Wainwright & Co. Maintains Buy on HOOKIPA Pharma, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on HOOKIPA Pharma and raised the price target from $5 to $6.
June 05, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on HOOKIPA Pharma and raised the price target from $5 to $6.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100